anti-allergic and anti-inflammatory activities of DS-4574, which possesses leukotriene antagonism and inhibits the release of immunologically stimulated mediators such as histamine and leukotrienes, were evaluated in several animal models. DS-4574 had dose-dependent inhibitory effects on IgE-mediated passive cutaneous anaphylaxis and the passive Arthus reaction in rats and the phase I response of Forssman antibody-induced bronchoconstriction.
Sulfidopeptide leukotrienes (LTs) as well as histamine are released from mast cells (1) and a variety of inflamma tory cells (2) . They are potent spasmogens of smooth mus cles in man and various animals (3) and cause increases in vascular permeability (4, 5) . These mediators have been implicated in the pathogenesis of inflammation and asth ma (2, 6) .
DS-4574 was chosen as the most promising of a series of thiadiazolo-pyrimidine derivatives that exhibit orally effective antiallergic action with LT antagonism. DS-4574 inhibited immunologically stimulated mediator release and act as LT antagonist (7, 8) . The allergic models em ployed in these previous studies measured the immediate hypersensitivity (Type I) response as defined by Coombs and Gell (9) . The pathogenesis of allergic disorders such as asthma is a complex and heterogenous process and in volves the action of a variety of mediators. Therefore, it is important to investigate the effects of DS-4574 on con ventional animal models of allergy and inflammation in addition to type I reactions.
The present experiments were performed to evaluate the effects of DS-4574 on types I -IV allergic animal models and some inflammatory animal models.
MATERIALS AND METHODS

Materials
DS-4574 (6-(2-cyclohexylethyl)- [1, 3, 4] etizolum and diso dium cromoglycate (DSCG) were prepared at our research institute. Other drugs and compounds were obtained from the following commercial sources: indomethacin, mepyramine, cyproheptadine, arachidonic acid and meth ylated bovine serum albumin (methylated BSA) (Sigma, St. Louis, MO, USA); Forssman antiserum (Cappel Laboratories, West Chester, PA, USA); urethane (Kishi da Kagaku, Tokyo); phenidone, Evans blue and succinyl choline (Tokyo Kasei, Tokyo); rabbit anti-rat serum (INC Immunobiologicals, Lisle, IL, USA); Freund's complete adjuvant (FCA) and Mycobacterium butyricum (Difco Laboratories, Detroit, MI, USA); liquid paraffin (Merck, Darmstadt, Germany); dexamethasome, hydrocortisone and cyclophosphamide (Shionogi Pharmaceutical Co., Ltd., Osaka); egg albumin (EA) and Bordetella pertussis toxin (Seikagaku Kogyo, Tokyo); platelet activating fac tor (PAF) (Bachem, Bubendorf, Switzerland); and leuko triene D4 (LTD4) (Wako, Osaka). Dinitrophenylated as caris (DNP-Asc) was prepared according to the method described by Strejan and Campbell (10) .
Drugs were suspended in 0.5% carboxymethyl cellulose (CMC) solution when used for oral administration. For intravenous injection and in vitro application, DS-4574 was dissolved in 0.1 N NaOH and diluted with saline or reaction medium. DS-4574 was given orally at 30 min be fore or intravenously at 1 min before administration of the stimulant.
Statistical analysis
The results were expressed as mean values±S.E. Statistical comparisons between groups were made by Student's t-test or Dunnett's multiple comparison test.
Animals
Sprague-Dawley and Lewis rats and C57BL/6 mice were purchased from Charles River Japan, Inc. (Atsugi). Donryu rats and Hartley guinea pigs and ddY mice were purchased from Japan SLC (Hamamatsu). The animals were kept in an animal room maintained at 23---'-2C and 55±15076 humidity and illuminated for 12 hr (8:00 20:00). The animals were deprived of food for 18 24 hr before the oral administration of the drugs, but water was provided ad libitum.
Preparation of antiserum
Rat anti-EA and anti-DNP-Asc antisera containing IgE were prepared by the methods described by Farmer et al. (11) and Tada and Okumura (12) , respectively. The pas sive cutaneous anaphylaxis (PCA) titers of these antisera were found to be about 1:512 and 1:128, respectively, when measured with the 48-hr PCA test in rats. These sera were inactivated by heating at 561C for 2 hr.
Anti-EA rabbit serum was prepared according to the procedures described by Goto et al. (13) . The PCA titer of the antiserum was found to be about 1:1280 when meas ured with the 4-hr PCA test in guinea pigs. These antisera were stored at 20V until use.
Type I allergic reaction PCA in rats: Male Sprague-Dawley rats weighing 175 270 g were used in groups of 5 animals. The diluted antiserum (0.05 ml) was injected into the shaved dorsal skin. Forty-eight hours after sensitization, the animals were challenged with 1 ml of saline containing 5 mg of an tigen and 5 mg Evans blue dye via the tail vein. Thirty minutes later, they were sacrificed, the dorsal skin was re moved and the exuded dye was measured. The extraction and measurement of the dye from the wheal sites were car ried out by the procedure described by Katayama et al. (14) .
Double sensitization with two IgE antibodies: The procedure used was that of Orr et al. (15) . Anti-EA and anti-DNP-Asc sera were diluted with saline to give an in tense blue wheal of approximately 20 pg of exudated dye 30 min after each antigen challenge. A 0.1-ml aliquot of the mixture of the two antibodies was injected intrader mally into the shaved dorsal skin, and 1 ml of saline con taining 5 mg of each antigen and 5 mg of Evans blue was injected intravenously 48 hr after sensitization.
Type II allergic reaction Forssman antibody-induced bronchoconstriction in guinea pigs: The procedure was based on the method described by Pelczarska and Roszkowski (16) . Male guinea pigs weighing 390-685 g were anesthetized with urethane (1.5 g/kg, i.p.). The trachea and jugular vein were cannulated, and the animals were ventilated artificial ly using a small respiratory pump (50-60 strokes/min, 4 6 ml/stroke). Bronchoconstriction was measured by the overflow technique of Konzett and Rossler (17) , as modified for electrical recording via a bronchospasm trans ducer (Ugo Basile 7020, Varese, Italy). Spontaneous breathing was arrested with succinylcholine (1 mg/kg) in jected intravenously about 5 min before the treatment with diluted antiserum (1 ml/kg) containing Forssman anti body. The bronchoconstriction was expressed as a percent age of the maximal overflow volume obtained by clamp ing off the trachea, and the percent inhibition was calculat ed based on the peak of the control bronchoconstriction.
Reverse cutaneous anaphylaxis in rats: Male Sprague Dawley rats weighing 160 185 g were used in groups of ten animals. Reverse cutaneous anaphylaxis was induced by the method of Unger et al. (18) . Anti-rat serum (0.05 ml) was injected into the shaved dorsal skin. Two hours later, the animals were sacrificed by decapitation and the dorsal skin was removed. The injected sites were punched out with a steel punch with an inside diameter of 12 mm after removal of the adherent connective tissue. Each piece of skin was weighed immediately after removal. The result was expressed by the following equation: Swelling
where Wi is the weight of the inflamed site and Ws is the weight of the saline-injected site. Complement dependent hemolysis and hypotonic hemolysis: Complement dependent hemolysis: The proce dures were based on Mayer's method (19) . The stock sus pension of sheep erythrocytes was washed three times with gelatin veronal buffer (GVB), and a 5% sheep erythrocyte suspension was prepared. A 0.25-ml aliquot of the 5% erythrocyte suspension was mixed with 3.75 ml of a solution consisting of 0.25 ml of diluted antiserum containing anti-sheep erythrocyte antibody as a source of complement, 2 ml of compound solution, 0.5 ml guinea pig serum as a source of complement and 1 ml GVB. The mixture was then incubated for 90 min at 37C. The reac tion was terminated by cooling the mixture on ice and cen trifuging at 150 x g for 10 min (41C).
Hypotonic hemolysis: The procedures were based on the method of Inglot and Wolna (20) . Protection and lysis of erythrocytes in hypotonic solution were determined by the release of hemoglobin. The stock suspension of sheep erythrocytes was washed three times with GVB and a 5% suspension of sheep erythrocytes was prepared. The ex periment was carried out as follows: 0.25 ml of the 5% erythrocyte suspension was mixed with 3.75 ml of hypo tonic solution containing the test compound. The hypo tonic solution was 10 mM phosphate buffer containing 90 mM NaCI (180 mOsm/kg). The mixture was left at room temperature for 5 min and was centrifuged for 5 min at 150 x g.
The hemolysis was expressed as a percentage of the com plete lysis caused by adding 3.75 ml of 0.1 % disodium car bonate solution to 0.25 ml of 5% erythrocyte suspension. The hemoglobin content of the clear supernatant was measured by a spectrophotometer at 540 nm. The inhibi tion was calculated as a percentage of the control value.
Type III allergic reaction Passive Arthus reaction in rats: The procedure was per formed by the method of Terasawa et al. (21) . Male Sprague-Dawley rats weighing 145 175 g were sensitized by intravenous injection of anti-EA rabbit serum (0.7 ml/100 g). Thirty minutes later, 0.1 ml of EA solution (0.25 mg/ml saline) were injected into the footpad. Foot swelling was measured at 0.5, 1, 2, 3 and 4 hr after anti gen challenge using an electronic water plethysmometer (Ugo Basile 7150).
Type IV allergic reaction
Delayed hypersensitivity response to methylated BSA in mice: The procedure of Crowle et al. was employed (22) . Male C57BL/6 mice weighing 17 23 g were used in each group of 8 animals. Mice were sensitized with a sub cutaneous injection of 0.1 ml emulsion consisting of equal volumes of methylated BSA (5 mg/ml) and FCA. Eight days later, 0.05 ml of 500 pg/ml methylated BSA in saline was injected into the plantar region of the right hind foot, and 0.05 ml saline was injected into the left hind foot as a control. The thickness of both hind feet was measured with a dial thickness gauge (Model G, Ozaki MFG Co., Ltd., Tokyo) before and 24 hr after challenge. The percent swelling of the antigen injected foot was calculated for comparison with the saline inject ed foot.
Inflammatory response
Carrageenin-induced edema in rats: Male Donryu rats weighing 120-140 g were used in groups of 7 animals. Edema was induced in the right hind paws of each rat by intraplantar injection of 0.1 ml of 1 % A-carrageenin. Paw volumes were measured plethysmometrically at 0.5, 1, 2, 3 and 4 hr after injection. Foot swelling was expressed as the percentage increase in paw volume, and the anti-in flammatory effect was expressed as the percentage inhibi tion in comparison to the vehicle-treated control value.
Adjuvant arthritis in rats: Female Lewis rats weighing 145 -170 g were used in groups of 7 animals. They were in jected intradermally in the left hind foot pad with 0.6 mg of Mycobacterium butyricum suspended in 0.1 ml of liquid paraffin. The degree of primary inflammation of the injected paw and that of secondary inflammation (polyarthritis) was followed for 4 weeks by recording the volume of the hind paws. The measurement of the hind paw volume was made by a water plethysmograph (Ugo Basile 7150). Foot pad swelling was calculated for com parison with foot pad volume before adjuvant injection.
PAF-induced pleurisy in rats: The procedure of Tarayre et al. was followed (23) . Male Sprague-Dawley rats weighing 200-250 g were anesthetized with ether. PAF solution (0.15 ml, 2 pg/rat) was injected into the pleural cavity just before the intravenous injection of Evans blue dye saline solution (1%, 2.5 ml/kg). Thirty minutes later, the animals were killed by decapitation, and the pleural cavity was opened and immediately rinsed with 5 ml saline containing 0.1 % EDTA. The recovered fluid was centrifuged at 3000 rpm for 10 min, and the ab sorbance of the supernatant was measured spectro photometrically at 620 nm as an index of the amount of Evans blue. Increased cutaneous vascular permeability induced by LTD4 in rats: Male Sprague-Dawley rats weighing 180-210 g were used in groups of 6 animals. Each animal was injected intradermally with LTD4 (500 ng/site) in 0.05 ml of saline in the shaved dorsal skin, and 5 mg of Evans blue in 1 ml saline was given intravenously via the tail vein. The animals were sacrificed 30 min after the in tradermal injection of LTD4. The exuded dye at each site was extracted and measured by the method of Katayama et al. (14) . The leakage of dye after intradermal injection of saline solution alone was quantified and subtracted from that resulting from intradermal injection of LTD4.
Arachidonic acid-induced ear edema in mice: Male ddY mice weighing 28 32 g were used in groups of 7 animals. Arachidonic acid was dissolved in acetone at a concentra tion of 100 mg/ml. Each mouse received 2 mg/ear of arachidonic acid on the right ear. The left ear (control) received acetone alone. The thickness of the right and left ears were measured with a dial thickness gauge 1 hr after arachidonic acid application. Ear edema was calculated by subtracting the thickness of the left ear (control) from that of the right ear (treated ear). 
RESULTS
Type I allergic reaction
Effect of DS-4574 on PCA in rats: As shown in Table 1 , DS-4574 at doses of 0.3 3 mg/kg inhibited the 48-hr PCA induced by DNP-Asc antigen on sensitized rats in a dose-dependent manner.
Effect of DS-4574 on PCA in double sensitization with two different IgE antibodies: In the two sequential anti gen challenge systems, there was a 4-hr interval between the first and second challenges, so that the effects of DS 4574 or DSCG could be excluded at the second antigen challenge.
As shown in Table 2 , the respective antigen challenge produced approximately equally potent reactions in rats sensitized with anti-EA and anti-DNP-Asc sera. The second challenge with the same antigen gave no PCA response regardless of whether DS-4574 or DSCG was ad ministered or not during the first antigen-antibody combi nation. Following the first challenge with EA or DNP-Asc in the absence of DS-4574 or DSCG, the second challenge with the alternative antigen (DNP-Asc or EA antigen) pro voked no PCA. In contrast, when DS-4574 or DSCG was given at the first antigen challenge, a typical PCA response to the second challenge with the alternative anti gen appeared. Therefore, this compound does not impair antigen-antibody combination but prevents the release of chemical mediators.
Effect of DS-4574 on the skin sensitization with IgE an tibody: To examine the influence of DS-4574 on the bind ing of IgE antibody to receptors on mast cells, anti-EA an tiserum was injected into rat back skin with or without DS-4574. The PCA reaction provoked by antigen (EA) 48 hr later was not altered by DS-4574 as shown by the fol lowing: The exuded dye was 28.5±4.8 pg/site in the con trol group given antiserum in the absence of DS-4574 and 27.9±4.8 pg/site in the group given antiserum in the presence of DS-4574 (100 pM). 
Effects of DS-4574 and other compounds on Forssman antibody-induced bronchoconstric tion in guinea pigs
All compounds were given intravenously 1 min before the Forssman serum challenge. Each value represents the mean±S.E. (n=5). *P <0.05, **P <0.01, showing significant differences from the con trol. DSCG: disodium cromoglycate. Type II allergic reaction Effect of DS-4574 on Forssman antibody-induced bron choconstriction in guinea pigs: The antiserum containing Forssman antibody induced biphasic bronchoconstriction in the guinea pigs. The initial increase (phase I) occurred within 1 min and was followed by a second increase (phase II), which was maximal between 2 to 4 min after the injection of antiserum. DS-4574 at doses of 1 to 10 mg/kg (i.v.) and LY171883, an LT antagonist, at a dose of 10 mg/kg (i.v.) inhibited only the phase I response (Table 3 ). Indomethacin at a dose of 5 mg/kg (i.v.) inhib ited both phase I and phase II responses but DSCG did not.
Effect of DS-4574 on reverse cutaneous anaphylaxis in rats: Table 4 shows that DS-4574 at doses of 30, 100 and 300 mg/kg (p.o.) did not inhibit this response. In con trast, dexamethasone at a dose of 0.5 mg/kg (p.o.) inhibit ed the response.
Effect of DS-4574 on complement dependent and hypo tonic hemolysis: DS-4574, LY171883 and mefenamic acid at a high concentration (10-3 M) inhibited complement dependent hemolysis by 93.3, 46.6 and 64.3% and hypo tonic hemolysis by 32.2, 44.4 and 64.5%, respectively; but at doses from 10-7 to 10-4 M, they inhibited comple ment-dependent and hypotonic hemolysis by less than 15% (data not shown).
Type III allergic reaction Effect of DS-4574 on passive Arthus reaction in rats: As shown in Table 5 , DS-4574 administered orally at doses of 10, 30 and 100 mg/kg dose-dependently inhibit ed footpad swelling induced by the Arthus reaction. Hydrocortisone at a dose of 100 mg/kg also inhibited this reaction. Cyproheptadine at a dose of 10 mg/kg inhibited only the early response.
Type IV allergic reaction
Effect of DS-4574 on delayed-type hypersensitivity response to methylated BSA in mice: As shown in Table  6 , DS-4574 at doses of 10, 30 and 100 mg/kg did not affect delayed-type hypersensitivity caused by methylated BSA in mice; however, cyclophosphamide at a dose of 10 mg/kg inhibited this response.
Inflammatory response
Effect of DS-4574 on carrageenin-induced paw edema in rats: DS-4574 at doses of 10, 30 and 100 mg/kg slightly inhibited the carrageenin-induced paw edema between 2 and 4 hr after carrageenin injection (Table 7) . Indometh acin at a dose of 3 mg/kg inhibited the paw edema sig nificantly between 2 and 4 hr after carrageenin injection. LY171883 did not affect the response between 0.5 and 4 hr after carrageenin injection.
Effect of DS-4574 on adjuvant arthritis in rats: DS 4574 at a dose of 100 mg/kg slightly inhibited the swelling of the non-injected foot but not that of the injected foot in the adjuvant arthritic rats (Fig. 1) , and it slightly re stored their body weight (data not shown). Effect of DS-4574 on PAF-induced pleurisy in rats: As shown in Table 8 Effect of DS-4574 on increased cutaneous vascular permeability induced by LTD4 in rats: Table 9 indicates that DS-4574 at doses of 3, 10 and 30 mg/kg (p.o.) inhib ited the increase in cutaneous vascular permeability in duced by LTD4. This response was also inhibited by an LT antagonist such as LY171883 (p.o.). Effect of DS-4574 on arachidonic acid-induced ear ede ma in mice: As shown in Table 10 , DS-4574 at doses of 30, 100 and 300 mg/kg (p.o.) inhibited arachidonic acid induced ear edema in a dose-dependent manner. Pheni done, a cyclooxygenase and lipoxygenase inhibitor, at a dose of 80 mg/kg (p.o.) also significantly inhibited this response. In contrast, indomethacin did not inhibit this response (data not shown). Table 8 .
Effects of DS-4574 and other compounds on PAF-induced pleurisy in rats DS-4574 was given orally 30 min before PAF injection. Etizolum, FPL-55712, indomethacin, mepyramine, cyproheptadine and DSCG were given intravenously 5 min before the PAF injection. Each value represents the mean ±S.E. (n=4 5). *P <0.05, **P <0.01, showing significant differences from the control. PAF: platelet activating fac tor, DSCG: disodium cromoglycate. 
DISCUSSION
We found that DS-4574 inhibited immediate hypersen sitivity reactions and bronchoconstriction induced by LTs and antigen. These effects of this compound are in accord ance with competitive LTD4 and LTE4 antagonism and immunological mediator release inhibition (7, 8) . In fur ther studies presented here, this compound inhibited the type III allergic response, one of the type II responses in addition to the type I allergic response, and some inflam matory responses in animal models.
DS-4574 inhibited the IgE-mediated PCA reaction and the immunological release of histamine or LTs (7) . So the site of action of this compound was further elucidated by different methods. Since a passive sensitization of the rat skin mast cells with IgE antibody was not affected by a high concentration of DS-4574, this compound could have no inhibitory effect on the IgE binding to the recep tors on the mast cells. In a double sensitization technique, the same antigen sequential challenge in the presence or absence of DS-4574 or DSCG does not produce a PCA reaction, suggesting that the initial antigen-antibody com bination occurs and results in a desensitization of the mast cells to the second antigen. On the contrary, the presence of DS-4574 or DSCG during the period of the 1st antigen-antibody combination completely preserved PCA responsiveness to the second challenge with another antigen, indicating that the mast cells kept an intact func tion to release mediators. In the absence of DS-4574 or DSCG during the period of the 1st antigen-antibody com bination, the second challenge with another antigen does not produce a PCA reaction because the chemical media tors released from the sensitized mast cells have already been depleted by the preceding antigen-antibody reaction. These findings suggest that DS-4574 as well as DSCG may not impair antigen-antibody combination but prevents the releasing process of chemical mediator such as hista mine.
The biphasic bronchoconstriction caused by Forssman antibody has been noted previously (16) . The activation of complement subsequent to the injection of Forssman antiserum is important for the increase in airway resistance, especially the phase II response (24) . Further more, the phase I bronchoconstriction was mediated by some mediators such as serotonin, prostaglandins and histamine, and the phase II response is due to obstruction resulting from endothelial damage and extravasation of hemorrhagic exudates into the respiratory tract (16) . In addition, it was reported recently that LTD4 and hista mine were not changed in the bronchoalveolar lavage fluids after Forssman anaphylaxis in guinea pigs (25) . DS 4574 and LY171883, which have LTs antagonistic activ ity, inhibited only the phase I response of the Forssman induced bronchoconstriction in guinea pigs in this experi ment. These results suggest that LT antagonists affect at least part of the phase I response of Forssman-induced bronchoconstriction, although the precise mechanism was not clear. In contrast, because DS-4574 did not in hibit the complement dependent hemolysis in vitro and reversed cutaneous anaphylaxis in vivo, this compound did not affect the complement activation.
The Arthus reaction is induced by deposits of immune complex in the vascular wall (26) . The deposition is fol lowed by the activation of the components of comple ment, resulting in the generation of the complement-de rived chemotactic factors C5a and C3a, which cause the accumulation of polymorphonuclear leukocytes (PMNs) at the inflammatory site. The response of Arthus pleurisy was caused by mediators such as histamine, serotonin and LTs (27, 28) , and complement anaphylatoxin C5a stimu lated leukotriene release in guinea pig lung tissue (29) . In this experiment, DS-4574 inhibited both the early and late responses. Cochrane (30) suggested the participation of IgE, IgG, basophilic leukocytes or mast cells in the early stage of the immune complex disease. Moreover, media tor release inhibitors such as DSCG and tranilast inhibit ed the Arthus reaction (31) . Therefore, the inhibitory effects of this compound on the type III allergic reaction are related at least in part to inhibitory activity against the release of mediators from the mast cells (7) and to LT an tagonistic activity (8) . Since the type III allergic reaction or complement activation is reported to be a primary cause of asthma in some patients (32) , the inhibitory effect of DS-4574 on type III allergic reactions is clinically beneficial for the treatment of bronchial asthma.
DS-4574 showed weak anti-inflammatory activity in car rageenin-induced edema, in arachidonic acid-induced ear edema and in a part of adjuvant arthritis. It should be em phasized that the doses required to inhibit these responses were higher than those inducing the inhibition of IgE mediated PCA. The activities in these models are associat ed with a non-specific anti-inflammatory action of this compound, because DS-4574 did not prevent the activity of either cyclooxygenase or lipoxygenase (S. Ono et al., unpublished observation), unlike a majority of the non steroidal anti-inflammatory agents. The inhibitory effect of this compound on carrageenin paw edema and ad juvant arthritis may be explained by the role of mediators from mast cells such as histamine, because histamine plays a role in the first phase of the edema (33) , and mast cells were involved in the pathogenesis in adjuvant arthri tis (34) .
Moreover, LTs have vascular permeability increasing activity and could be important in inflammatory condi tions (2). Tarayre et al. (23) have reported that a clear in crease of LTs was found in the pleural exudates after in jection of PAF. DS-4574 inhibited PAF-induced pleurisy at similar doses in cutaneous vascular permeability in creased by LTD4. Therefore, the antagonistic activity of this compound against LTs may explain the inhibition of these inflammatory responses. Arachidonic acid-induced ear edema was inhibited by phenidone, cyclooxygenase and lipoxygenase inhibitor, but not by indomethacin (35) . Though this response was mediated by LTs, at least part ly, inhibition of this response required higher doses of DS-4574 than those producing inhibition of the increased cutaneous vascular permeability induced by LTD4. The precise mechanism of action of this compound on these models remains to be elucidated. The inhibitory effect of DS-4574 on some inflammatory responses is beneficial for the treatment of bronchial asthma, because inflammation in the airways plays an important role in the pathogenesis of bronchial asthma (36) .
In conclusion, DS-4574 had anti-allergic activity in the type III allergic reaction in addition to the type I allergic reaction and anti-inflammatory activities in several ani mal models. Therefore, this compound could be useful for the treatment of bronchial asthma.
